Evidence by tier

Peptides graded
by evidence

Twelve peptides, ordered by the strongest study design that exists for each, with approval and sport status. A grade shows how far the research has gone, not whether a compound does anything.

Short answerCompound research · 8 min read · Updated 21 Nov 2026

This page orders twelve peptides by the strongest study design that exists for each. Approved medicines come first, then peptides with a peer-reviewed controlled study in people but no approval, then those without one. Each row gives its approval and sport status, checked on 21 November 2026. A higher grade is not a recommendation.

Key takeaways

  • Four of the twelve are approved medicines: semaglutide, tirzepatide, oxytocin and elamipretide, each for the uses and populations on its own label.
  • Four have peer-reviewed controlled studies in people and are not FDA-approved: retatrutide and thymosin alpha 1 in phase 3 trials, GHK-Cu in randomised trials on skin wounds and skin care, and kisspeptin in small studies.
  • For BPC-157, TB-500, MOTS-c and KPV we found no peer-reviewed controlled study in people (PubMed, 21 November 2026); BPC-157’s randomised data exist only as conference abstracts, and FDA staff’s searches did not identify clinical studies of MOTS-c or KPV in humans.
  • WADA’s 2026 and 2027 Lists name BPC-157, TB-500, kisspeptin and MOTS-c, prohibited at all times; its notes say a peptide not specifically named “may still be prohibited”.
  • A grade records study design. Two placebo-controlled phase 3 trials of thymosin alpha 1, in hepatitis B and in sepsis, found no significant effect on their primary outcomes.

01How are the peptides on this page graded?

If you searched for “best peptides”, the honest reply is that the word has no single meaning: it depends on the question, the person and the use. What can be put in order is the evidence. This page takes twelve peptides from our library and grades each by the strongest study design that exists for it.

Three tiers: no peer-reviewed controlled study in people at the bottom, controlled studies in people in the middle, approved medicines on top. The flag is a regulator’s approval.

Within each row, the tier codes are the ones on our guides: T1 a randomised trial in people, T2 a small or uncontrolled human study, T3 an animal study, T4 a cell study. The method is on evidence grades. Compounds that act on growth hormone are not covered on this page.

02Which peptides have the strongest study designs behind them?

Twelve peptides, strongest evidence first. Every cell was checked against its source on 21 November 2026. A grade describes study design. It is not a recommendation, and it says nothing about any product sold under the same name.

PeptideWhat it isStrongest study design that existsApproval status (where we checked)Sport status (WADA)
SemaglutideA GLP-1 receptor agonist, described on its label as a GLP-1 analog. A prescription medicine (Ozempic, Rybelsus, Wegovy).Tier 1. T1, approved. Randomised, double-blind, placebo-controlled trials; STEP 1 enrolled 1,961 adults without diabetes for 68 weeks.Yes. FDA first approved it in 2017 (Ozempic). Wegovy’s US label covers, among other uses, reducing excess body weight in adults and children aged 12 and over with obesity, and in adults with overweight who have a weight-related condition, with diet and physical activity. Research-grade material sold under the name is not these medicines.Not named on the 2026 or 2027 Prohibited List. On WADA’s 2027 Monitoring Program, which covers substances “not on the Prohibited List” that WADA wishes to monitor.
TirzepatideOne peptide that acts on two receptors, GIP and GLP-1. A prescription medicine (Mounjaro, Zepbound).Tier 1. T1, approved. Phase 3, randomised, double-blind trials; SURMOUNT-1 enrolled 2,539 adults without diabetes for 72 weeks.Yes. Mounjaro’s US label includes blood-sugar control in adults and children aged 10 and over with type 2 diabetes. Zepbound’s covers reducing excess body weight in adults with obesity, or overweight with a weight-related condition, and moderate to severe obstructive sleep apnoea in adults with obesity. Research-grade material is not these medicines.Not named on the 2026 or 2027 Prohibited List. On WADA’s 2027 Monitoring Program, which covers substances “not on the Prohibited List” that WADA wishes to monitor.
OxytocinA hormone of nine amino acids. Synthetic oxytocin is a prescription medicine (Pitocin).Tier 1. Approved. This row rests on its US label, not on individual trials.Yes. Pitocin’s US label covers starting or improving contractions of the uterus when there is a medical reason for delivery, and controlling bleeding after birth. It states that Pitocin “is not indicated for elective induction of labor”.Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”.
Elamipretide (SS-31)A peptide of four amino acids that binds cardiolipin in mitochondria. The active ingredient of Forzinity.Tier 1. T1, small. A randomised, double-blind, placebo-controlled crossover trial in 12 people with Barth syndrome, in which it “was not superior to placebo” on the two primary endpoints, and an open-label extension. A phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints.Yes, under accelerated approval (19 Sep 2025): “to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg”, based on an intermediate endpoint. Products sold online as SS-31 are not that medicine.Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”.
RetatrutideAn investigational drug from Eli Lilly: one peptide that acts on the GIP, GLP-1 and glucagon receptors. Not an approved medicine. Every published trial tested Lilly’s product; material sold online under the name has not been through those trials.Tier 2. T1, investigational. Phase 3, randomised, double-blind, placebo-controlled trial (TRIUMPH-1): 2,339 adults with obesity and no diabetes, 80 weeks; funded by the developer.Drugs@FDA lists no product (21 Nov 2026). FDA says it “cannot be used in compounding under federal law” and has “not been found safe and effective for any condition”.Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”.
Thymosin alpha 1A peptide of 28 amino acids, also called thymalfasin.Tier 2. T1. Placebo-controlled phase 3 trials in 97 adults with chronic hepatitis B (1999) and 1,106 adults with sepsis (2025); neither found a significant effect on its primary outcome.Not FDA-approved. FDA’s 2024 review cites approvals in Italy, India and Hong Kong, and describes Zadaxin as “a finished drug product available in other countries”. Products sold online as thymosin alpha 1 are not those medicines.Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”.
GHK-CuA peptide of three amino acids (glycine, histidine, lysine) bound to copper.Tier 2. T1. Randomised trials on skin wounds and on skin care. The one PubMed-indexed randomised trial of a skin-care regimen, after laser resurfacing (13 completers, 2006): blinded and computer assessments found no significant difference between groups; a patient questionnaire did differ (P = .04).No medicine containing it appears in Drugs@FDA (21 Nov 2026). Cosmetic ingredients do not require FDA approval before sale.Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”.
KisspeptinA hormone encoded by the KISS1 gene, with forms from kisspeptin-54 down to kisspeptin-10.Tier 2. T2. Human genetics studies, and small studies that measured hormone levels, such as a double-blind, placebo-controlled crossover study in 6 men (2005).FDA staff, 2024: “There is no approved product in any country containing kisspeptin-10”. Kisspeptin-10 has been in FDA’s compounding Category 2 since 29 Sep 2023.Named in class S2, in an entry for males (S2.2.1); prohibited at all times.
BPC-157A synthetic peptide of 15 amino acids.Tier 3. Mostly T3 and T4: 35 of the 36 studies in a 2025 systematic review of musculoskeletal research were preclinical. In people (T2), the only randomised, placebo-controlled data are conference abstracts from 2002 to 2005. A randomised phase 2 trial is recruiting.FDA staff’s 2026 search found it in no approved product in any country. Named in HHS’s October 2026 draft policy for licensed compounders, which is not binding and not an approval.Named in class S0, non-approved substances; prohibited at all times.
TB-500A synthetic fragment, seven amino acids long, of the protein thymosin β4.Tier 3. T3 and T4. FDA staff found no article in which it was given to humans; a later 2026 report describes three patients given it with other agents, without a control group. A randomised phase 1/2 trial is recruiting.FDA staff found no approved product containing it in Canada, Australia, the United Kingdom or seven other European countries, and none authorised by the European Medicines Agency. Named in HHS’s October 2026 draft policy for licensed compounders, which is not binding and not an approval.Named in class S2: “Thymosin-β4 and its derivatives e.g. TB-500”; prohibited at all times.
MOTS-cA peptide of 16 amino acids encoded in mitochondrial DNA, first reported in 2015.Tier 3. T3 and T4 for studies that gave it. FDA staff “did not identify data, such as clinical studies, evaluating the administration of MOTS-c to humans”. A randomised phase 2 trial is recruiting.Drugs@FDA lists no product (21 Nov 2026), and FDA staff found none listed by the European Medicines Agency. Named in HHS’s October 2026 draft policy for licensed compounders, which is not binding and not an approval.Named in class S4, metabolic modulators (S4.4.1); prohibited at all times.
KPVA peptide of three amino acids (lysine, proline, valine). FDA’s 2026 briefing describes it as a fragment of the hormone α-MSH.Tier 3. T3 and T4: mouse colitis models and human cells in a dish (2008). FDA staff’s search “did not identify data, such as clinical studies, on the use of KPV in humans”, and ClinicalTrials.gov lists no trial (21 Nov 2026).Drugs@FDA lists no product (21 Nov 2026), and FDA staff found none listed by the European Medicines Agency. Named in HHS’s October 2026 draft policy for licensed compounders, which is not binding and not an approval.Not named on the 2026 or 2027 Prohibited List. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”.

Guides: semaglutide, tirzepatide, oxytocin, SS-31, retatrutide, thymosin alpha 1, GHK-Cu, kisspeptin, BPC-157, TB-500, MOTS-c, KPV. Sport rules in full: peptides and anti-doping.

03What do the three tiers mean?

The tiers are about what has been tested, and how. Inside a tier, rows run from the stronger study designs to the weaker.

Tier 1

Approved medicine

A regulator has reviewed the evidence and approved a product for the uses on its label. Four of the twelve: semaglutide, tirzepatide, oxytocin and elamipretide. The approval belongs to the product, not to everything sold under the compound’s name.

Tier 2

Controlled studies in people, no approval

Peer-reviewed controlled studies in people exist, from phase 3 trials (retatrutide, thymosin alpha 1) to randomised trials on skin wounds and skin care (GHK-Cu) and small hormone studies (kisspeptin). None is an FDA-approved medicine.

Tier 3

No peer-reviewed controlled study in people

BPC-157, TB-500, MOTS-c and KPV. Most studies that gave them are in animals and cells. In people, BPC-157 has small uncontrolled studies and randomised data published only as conference abstracts, and one uncontrolled report describes three patients given TB-500 with other agents. We found no peer-reviewed controlled study of any of the four in people (PubMed, 21 November 2026).

04What can’t an evidence grade tell you?

Whether it works.

A grade records the design of a study, not its finding. Two placebo-controlled phase 3 trials of thymosin alpha 1 found no significant effect on their primary outcomes.

Whether it is safe.

Design says little about harm. Approved labels carry warnings, and for BPC-157 FDA staff found “insufficient clinical safety information to characterize the safety profile”. See are peptides safe.

What is in a vial.

Evidence belongs to the molecule a study tested. Whether a given vial contains that molecule is a separate question, and only a lab test of that sample answers it.

What the rules are where you live.

Approval and sport status are two facts among several, and rules differ by country. See are peptides legal.

Why photos and testimonials cannot stand in for any of these: do peptides work?

05What we don’t know

  • What the trials now recruiting will show for BPC-157, TB-500 and MOTS-c. Each has a randomised trial registered, with nothing posted yet.
  • Whether retatrutide will be approved. It is investigational, and Drugs@FDA lists no product (21 November 2026).
  • Whether elamipretide’s accelerated approval will be confirmed. Its label says continued approval “may be contingent upon verification and description of clinical benefit in a confirmatory trial”.
  • How compounds outside this page would grade. Twelve are covered here; each guide in our library carries its own grade.

How the prescription route is regulated: what is peptide therapy? New studies and rule changes, once a week: the 6:00 brief.

This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not medical or legal advice. For anything about your health, a doctor who knows you is the right call.

RefSources

  1. World Anti-Doping Agency. The Prohibited List 2026 and 2027 (S0, S2.2.1, S2.3, S4.4.1), the 2027 List summary of major modifications and explanatory notes (undated in its text), and the 2027 Monitoring Program (item 6). International Standard and companion documents; PDFs downloaded from wada-ama.org and searched 21 Nov 2026 (List files SHA-1 08b06d5a… and 8e84d248…). www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  2. Drugs@FDA via openFDA: approved products for semaglutide (Ozempic, first approved 5 Dec 2017), tirzepatide, oxytocin (Pitocin) and elamipretide (Forzinity, 19 Sep 2025); no product for BPC-157, TB-500, thymosin, timbetasin, MOTS-c, KPV, prezatide, copper tripeptide, kisspeptin, retatrutide or thymalfasin. Database queries, data updated 20 Nov 2026; run 21 Nov 2026. open.fda.gov/apis/drug/drugsfda/
  3. Novo Nordisk. Wegovy (semaglutide) US prescribing information: sections 1 and 11. DailyMed label, effective 18 Jun 2026; read 21 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2a…
  4. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. [Randomised, double-blind, placebo-controlled trial of semaglutide in 1,961 adults with overweight or obesity (STEP 1).] N Engl J Med, 2021;384(11):989–1002. PMID 33567185 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/33567185/
  5. Eli Lilly. Zepbound and Mounjaro (tirzepatide) US prescribing information: section 1. Labels via openFDA (Zepbound effective 28 Aug 2026; Mounjaro, a repackager’s copy effective 29 Jul 2026); read 21 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-43…
  6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. [Phase 3, randomised, double-blind, placebo-controlled trial of tirzepatide in 2,539 adults with obesity or overweight (SURMOUNT-1).] N Engl J Med, 2022;387(3):205–216. PMID 35658024 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/35658024/
  7. Par Health. Pitocin (oxytocin injection, USP) prescribing information: description, indications and usage. Label via openFDA, effective 6 May 2026; read 21 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d4b2c25-2e…
  8. Stealth BioTherapeutics. Forzinity (elamipretide) US prescribing information: sections 1, 11 and 14. Label via openFDA, effective 6 Nov 2026; read 21 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76…
  9. Karaa A, Bertini E, Carelli V, et al. [Phase 3, randomised, double-blind, placebo-controlled trial of elamipretide in 218 adults with primary mitochondrial myopathy (MMPOWER-3).] Neurology, 2023;101(3):e238–e252. PMID 37268435 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/37268435/
  10. Jastreboff AM, Kaplan LM, Davies MJ, et al. [Phase 3, randomised, double-blind, placebo-controlled trial of retatrutide in 2,339 adults with obesity (TRIUMPH-1).] N Engl J Med, 2026;395(18):1781–1793. PMID 42814954 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/42814954/
  11. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss (retatrutide and compounding). Web page, content current as of 1 Oct 2026; read 21 Nov 2026. www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-u…
  12. Mutchnick MG, Lindsay KL, Schiff ER, et al. [Phase III, randomised, double-blind, placebo-controlled trial of thymosin alpha 1 in 97 patients with chronic hepatitis B.] J Viral Hepat, 1999;6(5):397–403. PMID 10607256 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/10607256/
  13. Wu J, Pei F, Zhou L, et al. [Phase 3, double-blind, placebo-controlled trial of thymosin α1 in 1,106 adults with sepsis (TESTS).] BMJ, 2025;388:e082583. PMID 39814420 (abstract read 21 Nov 2026); correction BMJ 2025;389:r1098, PMID 40447307. pubmed.ncbi.nlm.nih.gov/39814420/
  14. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 4 December 2024: thymosin alpha-1-related bulk drug substances (PDF pp. 12, 13, 26). Advisory committee briefing, memo dated 15 Nov 2024; read 21 Nov 2026. www.fda.gov/media/183820/download
  15. Miller TR, Wagner JD, Baack BR, Eisbach KJ. [Randomised trial of skin-care regimens with and without a copper tripeptide complex after laser resurfacing; 13 completers.] Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/16847171/
  16. U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). FDA page, content current as of 11 Sep 2024; read 21 Nov 2026. www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic…
  17. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 29 October 2024: kisspeptin-10 (PDF pp. 13, 25). Advisory committee briefing, memo dated 5 Jul 2024; read 21 Nov 2026. www.fda.gov/media/182089/download
  18. Kisspeptin studies in people: de Roux N et al., Proc Natl Acad Sci U S A 2003;100(19):10972–10976 (PMID 12944565); Seminara SB et al., N Engl J Med 2003;349(17):1614–1627 (PMID 14573733); Dhillo WS et al., [double-blind, placebo-controlled crossover study of kisspeptin-54 in 6 men], J Clin Endocrinol Metab 2005;90(12):6609–6615 (PMID 16174713). Abstracts read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=12944565+OR+14573733+OR+161747…
  19. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 table: kisspeptin-10, added 29 Sep 2023). Web page, content current as of 22 Apr 2026; read 21 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  20. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 2025;21(4):485–495. PMID 40756949 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/40756949/
  21. U.S. Food and Drug Administration. FDA briefing documents, Pharmacy Compounding Advisory Committee, 23–24 July 2026: BPC-157 (PDF pp. 24, 27, 43), KPV (fda.gov/media/193346, PDF pp. 7, 10, 17, 20), MOTS-c (fda.gov/media/193347, PDF pp. 19, 31) and TB-500 (fda.gov/media/193349, PDF pp. 20, 21). Advisory committee briefings, memos dated 11 to 15 May 2026; read 21 Nov 2026. www.fda.gov/media/193343/download
  22. Froum S, Estrin N, Pico G, et al. [Narrative review with three uncontrolled clinical cases given several agents, including BPC-157 and TB-500.] Front Oral Health, 2026;7:1907109. PMID 42876687 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/42876687/
  23. Lee C, Zeng J, Drew BG, et al. [First report of MOTS-c, a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA; cell and mouse studies.] Cell Metab, 2015;21(3):443–454. PMID 25738459 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/25738459/
  24. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. [KPV in human intestinal and immune cells and in two mouse colitis models.] Gastroenterology, 2008;134(1):166–178. PMID 18061177 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/18061177/
  25. ClinicalTrials.gov records NCT07437547 (BPC-157, phase 2), NCT07487363 (TB-500, phase 1/2) and NCT07505745 (MOTS-c, phase 2), all randomised and recruiting with no data posted; no record for KPV. Registry API v2, read 21 Nov 2026. clinicaltrials.gov/study/NCT07487363
  26. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Appendix A; and Federal Register notice 91 FR 68526 (FR Doc. 2026-22192, 30 Oct 2026). Policy document: hhs.gov returned 403 on 21 Nov 2026, read on the Internet Archive capture of 11 Nov 2026, the newest; notice read on govinfo 21 Nov 2026. web.archive.org/web/20261111210456/https://www.hhs.gov/sites…

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Which peptides on this page are FDA-approved medicines?

Four of the twelve: semaglutide, tirzepatide, oxytocin and elamipretide, each for the uses and populations on its own label. Research-grade material sold under those names is not those medicines.

Does a higher evidence grade mean a peptide works?

No. A grade records study design, not the finding. Two placebo-controlled phase 3 trials of thymosin alpha 1, in hepatitis B and in sepsis, found no significant effect on their primary outcomes.

Which peptides on this page does WADA prohibit by name?

The 2026 and 2027 Prohibited Lists name BPC-157 (class S0), TB-500 and kisspeptin (class S2) and MOTS-c (class S4), prohibited at all times. WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”.

Is BPC-157 an approved medicine anywhere?

FDA staff’s 2026 search found BPC-157 in no approved product in any country. HHS named it in an October 2026 draft policy for licensed compounders, which is not binding and not an approval.

Why are some peptides missing from this page?

The page grades twelve peptides that have a 6AM guide. Compounds that act on growth hormone are not covered here.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page